Abstract
The ancillary analysis of the KYOTO HEART Study (n = 3031) was designed to assess the combined treatment with calcium channel blocker (CCB) plus valsartan for high-risk hypertension. With-CCB (n = 1807) showed less primary events than without-CCB (n = 1224) (P = .037), in which acute myocardial infarction was significantly reduced. With-CCB plus valsartan (n = 773) showed lower incidence than with-CCB plus non-angiotensin receptor blocker (ARB) (n = 1034) (P = .0002), in which angina pectoris and heart failure were significantly reduced. Without-CCB plus valsartan (n = 744) was superior to without-CCB plus non-ARB (n = 480) (P = .0013), in which stroke was reduced. CCB-based therapy was useful, and CCB plus valsartan combination provided a more efficient prevention for high-risk hypertensive patients.
Publication types
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angina Pectoris / prevention & control
-
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
-
Antihypertensive Agents / administration & dosage*
-
Blood Pressure / drug effects
-
Calcium Channel Blockers / administration & dosage*
-
Cardiovascular Diseases / prevention & control*
-
Female
-
Heart Failure / prevention & control
-
Humans
-
Hypertension / drug therapy*
-
Hypertension / physiopathology
-
Japan
-
Male
-
Middle Aged
-
Myocardial Infarction / prevention & control
-
Risk Factors
-
Stroke / prevention & control
-
Tetrazoles / administration & dosage*
-
Valine / administration & dosage
-
Valine / analogs & derivatives*
-
Valsartan
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Tetrazoles
-
Valsartan
-
Valine